JP2016190847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016190847A5 JP2016190847A5 JP2016087432A JP2016087432A JP2016190847A5 JP 2016190847 A5 JP2016190847 A5 JP 2016190847A5 JP 2016087432 A JP2016087432 A JP 2016087432A JP 2016087432 A JP2016087432 A JP 2016087432A JP 2016190847 A5 JP2016190847 A5 JP 2016190847A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion polypeptide
- amino acid
- acid sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims 44
- 230000004927 fusion Effects 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims 6
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 102000015834 Klotho Human genes 0.000 claims 4
- 108050004036 Klotho Proteins 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101001139093 Homo sapiens Klotho Proteins 0.000 claims 2
- 102100020686 Klotho Human genes 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102100020683 Beta-klotho Human genes 0.000 claims 1
- 101710104526 Beta-klotho Proteins 0.000 claims 1
- 208000024806 Brain atrophy Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 201000009856 cataract 30 Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003468 luciferase reporter gene assay Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000003098 myoblast Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/696,693 | 2010-01-29 | ||
| US12/696,693 US8420088B2 (en) | 2008-01-28 | 2010-01-29 | Methods and compositions using FGF23 fusion polypeptides |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550437A Division JP5964243B2 (ja) | 2010-01-29 | 2011-01-27 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016190847A JP2016190847A (ja) | 2016-11-10 |
| JP2016190847A5 true JP2016190847A5 (enExample) | 2017-01-19 |
Family
ID=43828141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550437A Expired - Fee Related JP5964243B2 (ja) | 2010-01-29 | 2011-01-27 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
| JP2016087432A Pending JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550437A Expired - Fee Related JP5964243B2 (ja) | 2010-01-29 | 2011-01-27 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8420088B2 (enExample) |
| EP (2) | EP3124612A1 (enExample) |
| JP (2) | JP5964243B2 (enExample) |
| KR (1) | KR20130032296A (enExample) |
| CN (3) | CN102725413B (enExample) |
| AR (1) | AR080043A1 (enExample) |
| AU (1) | AU2011209380B2 (enExample) |
| CA (1) | CA2787285A1 (enExample) |
| EA (1) | EA201201047A1 (enExample) |
| ES (1) | ES2605302T3 (enExample) |
| MX (1) | MX336391B (enExample) |
| PL (1) | PL2529016T3 (enExample) |
| PT (1) | PT2529016T (enExample) |
| TW (2) | TWI430805B (enExample) |
| UY (1) | UY33204A (enExample) |
| WO (1) | WO2011092234A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| CA2835607C (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN102961739A (zh) * | 2012-12-12 | 2013-03-13 | 黄曙 | Klotho蛋白的用途 |
| US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US20160120959A1 (en) * | 2013-03-14 | 2016-05-05 | The Board Of Regents Of The University Of Oklahoma | Use of Klotho Nucleic Acids or Proteins for Treatment of Diabetes and Diabetes-Related Conditions |
| KR101492710B1 (ko) * | 2013-04-03 | 2015-02-13 | 중앙대학교 산학협력단 | Fgf23 유전자를 이용한 전립선암 진단용 마커 및 이를 이용한 전립선암 예측 및 진단 방법 |
| JP6159930B2 (ja) | 2013-10-24 | 2017-07-12 | 地方独立行政法人東京都健康長寿医療センター | 筋幹細胞又は筋芽細胞、及びそれを用いた代謝変換に関与する物質のスクリーニング方法、並びにスクリーニング方法によって得られた物質を含む医薬組成物 |
| JP6560202B2 (ja) | 2013-10-28 | 2019-08-21 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 癌モデル及び関連方法 |
| AU2014348657A1 (en) | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| EP3738981A1 (en) | 2014-01-24 | 2020-11-18 | NGM Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
| JP6370577B2 (ja) * | 2014-03-26 | 2018-08-08 | 国立大学法人京都工芸繊維大学 | 抗老化物質のスクリーニング方法 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| EA201791238A1 (ru) * | 2014-12-04 | 2018-02-28 | Новартис Аг | Способы и композиции, в которых используются варианты полипептидов klotho |
| EP3957317A1 (en) | 2015-02-06 | 2022-02-23 | The Regents of The University of California | Methods and compositions for improved cognition |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| BR112018073909A2 (pt) * | 2016-06-02 | 2019-02-26 | Klotho Therapeutics, Inc. | proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas |
| EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN106317226B (zh) * | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| BR112021020888A2 (pt) * | 2019-04-19 | 2021-12-21 | Genethon | Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23 |
| WO2021128065A1 (zh) * | 2019-12-25 | 2021-07-01 | 广州菲康生物技术有限公司 | 人fgf-23的荧光免疫层析试纸和人fgf-23的荧光免疫层析检测试剂盒 |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| US20250154487A1 (en) * | 2023-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5541094A (en) * | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
| AU709323B2 (en) | 1996-03-15 | 1999-08-26 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| CN1167795C (zh) | 1996-12-26 | 2004-09-22 | 协和发酵工业株式会社 | 肽、dna及抗体 |
| US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| EP1068356B8 (en) | 1998-04-03 | 2007-01-03 | Adnexus Therapeutics, Inc. | Addressable protein arrays |
| US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| DE60026287T2 (de) | 1999-04-22 | 2006-08-17 | Liposcience, Inc. | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 |
| US6569624B1 (en) | 1999-08-12 | 2003-05-27 | Wisconsin Alumni Research Foundation | Identification of genetic markers of biological age and metabolism |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| JP2006238894A (ja) * | 2000-02-15 | 2006-09-14 | Amgen Inc | 線維芽細胞成長因子−２３分子およびその使用 |
| JP2003531583A (ja) | 2000-03-08 | 2003-10-28 | カイロン コーポレイション | ヒトｆｇｆ−２３遺伝子および遺伝子発現産物 |
| DE60141582D1 (de) | 2000-07-19 | 2010-04-29 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
| CA2436661A1 (en) | 2001-01-30 | 2002-08-08 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acid and polypeptide molecules |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| WO2002088358A2 (en) * | 2001-04-26 | 2002-11-07 | Geneprot, Inc. | Human fibroblast growth factor-related compositions |
| EP1327443A1 (en) | 2001-12-21 | 2003-07-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein |
| US20050004348A1 (en) * | 2002-12-23 | 2005-01-06 | Miyamoto Ken-Ichi | Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US20110015345A1 (en) * | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
| EA032727B1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Мутантный резистентный к протеолизу полипептид fgf21 и его применение |
| EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2010
- 2010-01-29 US US12/696,693 patent/US8420088B2/en not_active Expired - Fee Related
-
2011
- 2011-01-27 AU AU2011209380A patent/AU2011209380B2/en not_active Ceased
- 2011-01-27 CN CN201180007622.1A patent/CN102725413B/zh active Active
- 2011-01-27 CA CA2787285A patent/CA2787285A1/en not_active Withdrawn
- 2011-01-27 WO PCT/EP2011/051112 patent/WO2011092234A1/en not_active Ceased
- 2011-01-27 UY UY0001033204A patent/UY33204A/es not_active Application Discontinuation
- 2011-01-27 EP EP16184724.9A patent/EP3124612A1/en not_active Withdrawn
- 2011-01-27 PT PT117058305T patent/PT2529016T/pt unknown
- 2011-01-27 CN CN201310049110.2A patent/CN103204941B/zh active Active
- 2011-01-27 PL PL11705830T patent/PL2529016T3/pl unknown
- 2011-01-27 JP JP2012550437A patent/JP5964243B2/ja not_active Expired - Fee Related
- 2011-01-27 CN CN201610245160.1A patent/CN105968208A/zh not_active Withdrawn
- 2011-01-27 AR ARP110100273A patent/AR080043A1/es unknown
- 2011-01-27 ES ES11705830.5T patent/ES2605302T3/es active Active
- 2011-01-27 EP EP11705830.5A patent/EP2529016B1/en active Active
- 2011-01-27 EA EA201201047A patent/EA201201047A1/ru unknown
- 2011-01-27 KR KR1020127022498A patent/KR20130032296A/ko not_active Withdrawn
- 2011-01-27 MX MX2012008780A patent/MX336391B/es unknown
- 2011-01-28 TW TW100103508A patent/TWI430805B/zh active
- 2011-01-28 TW TW103100421A patent/TWI569805B/zh not_active IP Right Cessation
-
2013
- 2013-03-12 US US13/796,711 patent/US8932589B2/en not_active Expired - Fee Related
-
2014
- 2014-11-03 US US14/531,620 patent/US9475857B2/en active Active
-
2016
- 2016-04-25 JP JP2016087432A patent/JP2016190847A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016190847A5 (enExample) | ||
| JP2017537926A5 (enExample) | ||
| JP2010519931A5 (enExample) | ||
| Wilson | Inhibition of protein–protein interactions using designed molecules | |
| JP2018538356A5 (enExample) | ||
| JP2018525989A5 (enExample) | ||
| JP2009525757A5 (enExample) | ||
| JP2016521688A5 (enExample) | ||
| JP2009513162A5 (enExample) | ||
| JP2018504911A5 (enExample) | ||
| JP2017506521A5 (enExample) | ||
| JP2013534812A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2012509687A5 (enExample) | ||
| JP2010065037A5 (enExample) | ||
| JP2012518420A5 (enExample) | ||
| JP2017070289A5 (enExample) | ||
| JP2021502378A5 (ja) | アクチビンＩＩａ型受容体変異体を含む医薬組成物 | |
| JP2014510519A5 (enExample) | ||
| JP2016527891A5 (enExample) | ||
| JP2019518788A5 (enExample) | ||
| ME02652B (me) | Stabilizovana varijanta aktivin iib receptora | |
| JP2013517781A5 (enExample) | ||
| JP2017533194A5 (enExample) | ||
| JP2012070739A5 (enExample) |